CoreCap Advisors LLC Has $1.92 Million Stock Holdings in Axon Enterprise, Inc. (NASDAQ:AXON)

CoreCap Advisors LLC grew its stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 15.7% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 3,223 shares of the biotechnology company's stock after buying an additional 437 shares during the period. CoreCap Advisors LLC's holdings in Axon Enterprise were worth $1,915,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of AXON. Cetera Investment Advisers boosted its position in Axon Enterprise by 1.0% during the 4th quarter. Cetera Investment Advisers now owns 23,009 shares of the biotechnology company's stock worth $13,675,000 after acquiring an additional 236 shares during the period. Bridgeway Capital Management LLC bought a new stake in shares of Axon Enterprise in the fourth quarter valued at approximately $3,506,000. Capstone Investment Advisors LLC lifted its position in Axon Enterprise by 4.7% in the fourth quarter. Capstone Investment Advisors LLC now owns 1,505 shares of the biotechnology company's stock worth $894,000 after purchasing an additional 67 shares during the period. Captrust Financial Advisors grew its stake in Axon Enterprise by 19.5% during the fourth quarter. Captrust Financial Advisors now owns 14,821 shares of the biotechnology company's stock worth $8,809,000 after buying an additional 2,415 shares during the last quarter. Finally, Baker Avenue Asset Management LP bought a new stake in shares of Axon Enterprise during the fourth quarter valued at approximately $255,000. 79.08% of the stock is owned by institutional investors and hedge funds.

Axon Enterprise Stock Performance

AXON traded down $2.24 on Friday, reaching $684.59. 642,401 shares of the stock were exchanged, compared to its average volume of 764,683. Axon Enterprise, Inc. has a fifty-two week low of $273.52 and a fifty-two week high of $715.99. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.96 and a quick ratio of 2.63. The firm has a market capitalization of $53.29 billion, a PE ratio of 176.90, a PEG ratio of 5.17 and a beta of 1.24. The company's 50-day moving average price is $564.50 and its 200 day moving average price is $584.84.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 EPS for the quarter, beating analysts' consensus estimates of $1.34 by $0.07. Axon Enterprise had a return on equity of 7.50% and a net margin of 15.37%. The business had revenue of $603.63 million during the quarter, compared to analysts' expectations of $585.67 million. During the same quarter in the prior year, the firm earned $1.15 earnings per share. The business's revenue was up 31.3% compared to the same quarter last year. As a group, sell-side analysts forecast that Axon Enterprise, Inc. will post 5.8 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

AXON has been the subject of several research analyst reports. JMP Securities reiterated an "outperform" rating on shares of Axon Enterprise in a report on Tuesday, February 4th. Needham & Company LLC increased their target price on shares of Axon Enterprise from $600.00 to $750.00 and gave the stock a "buy" rating in a research report on Thursday. Barclays raised their price objective on Axon Enterprise from $726.00 to $735.00 and gave the company an "overweight" rating in a research note on Friday. The Goldman Sachs Group increased their price objective on Axon Enterprise from $500.00 to $700.00 and gave the company a "buy" rating in a report on Monday, January 27th. Finally, Craig Hallum downgraded shares of Axon Enterprise from a "buy" rating to a "cautious" rating in a research report on Monday, March 10th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, Axon Enterprise currently has an average rating of "Moderate Buy" and a consensus price target of $640.91.

Insider Activity

In other news, CEO Patrick W. Smith sold 10,000 shares of the business's stock in a transaction on Monday, April 21st. The shares were sold at an average price of $540.99, for a total transaction of $5,409,900.00. Following the completion of the sale, the chief executive officer now directly owns 3,063,982 shares of the company's stock, valued at $1,657,583,622.18. The trade was a 0.33 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Jeri Williams sold 307 shares of the business's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $552.72, for a total value of $169,685.04. Following the completion of the transaction, the director now owns 1,627 shares in the company, valued at approximately $899,275.44. This trade represents a 15.87 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 4.40% of the company's stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.